This drug delivery system was expected to enhance the accuracy therapeutic effect of the positive expression of EGFR NSCLC cells, reduce the toxicity on other major organs, and improve the application of the low solubility chemotherapy drugs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.